2m 2m 2m 2m 2m 2m 2m
Axsome Therapeut (AXSM)
NASDAQ
$245.22-$2.63 (-1.06%)
Price as of Jun 23, 2026 7:54 PM EDT- $12.8BMarket Cap
- 143.83%1-Year Change
- BiotechnologyIndustry
Axsome Therapeut (AXSM)
$245.22-$2.63 (-1.06%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 633.8M +64.33% | 385.7M +42.53% | 270.6M +440.80% | 50.0M N/A | |
Cost of Revenue | 47.5M +42.56% | 33.3M +27.77% | 26.1M +401.48% | 5.2M N/A | |
Gross Profit | 586.3M +66.38% | 352.4M +44.11% | 244.5M +445.36% | 44.8M N/A | |
Sales and Marketing Expense | 570.6M +38.71% | 411.4M +27.31% | 323.1M +102.90% | 159.3M N/A | |
Research and Development Expense | -183.3M -2.03% | -187.1M +91.00% | -97.9M +69.02% | -57.9M -0.20% | |
Depreciation and Amortization Expense | 6.4M -0.27% | 6.4M +0.27% | 6.4M +54.01% | 4.1M +5,321.39% | |
Total Operating Expenses | 805.3M +20.86% | 666.3M +32.61% | 502.4M +118.60% | 229.8M +84.30% | |
Operating Profit | -166.8M -40.56% | -280.6M +21.02% | -231.8M +28.94% | -179.8M +44.18% | |
Interest Income | 9.4M -37.58% | 15.0M N/A | N/A N/A | N/A N/A | |
Interest Expense | -15.9M -26.19% | -21.6M N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | -6.6M -0.18% | -6.6M N/A | 0 N/A | 0 N/A | |
Total Nonoperating Income and Expense | -15.9M -26.19% | -21.6M N/A | N/A N/A | N/A N/A | |
Income before Taxes | -183.7M -36.02% | -287.1M +20.50% | -238.3M +32.52% | -179.8M +44.18% | |
Income Taxes | -530,000 -723.53% | 85,000 -91.15% | 960,000 N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -183.2M -36.22% | -287.2M +20.05% | -239.2M +27.84% | -187.1M +43.50% | |
Net Income from Continuing Operations Applicable to Common | -183.7M -36.02% | -287.1M +20.50% | -238.3M +27.33% | -187.1M +43.50% | |
Basic EPS and Net Income | -3.68 -38.56% | -5.99 +13.66% | -5.27 +14.57% | -4.60 +32.56% | |
Diluted EPS and Net Income | -3.68 -38.56% | -5.99 +13.66% | -5.27 +14.57% | -4.60 +32.56% | |
Basic Weighted Average Shares | 49.7M +3.83% | 47.9M +5.48% | 45.4M +11.73% | 40.7M +8.07% | |
Diluted Weighted Average Shares | 49.7M +3.83% | 47.9M +5.48% | 45.4M +11.73% | 40.7M +8.07% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 322.9M +2.40% | 315.4M -18.34% | 386.2M +92.29% | 200.8M +132.26% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 322.9M +2.40% | 315.4M -18.34% | 386.2M +92.29% | 200.8M +132.26% | |
Total Current Assets | 589.0M +21.42% | 485.1M -3.81% | 504.3M +105.28% | 245.6M +183.92% | |
Accumulated Depreciation | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | 562,000 -3.77% | 584,000 -30.97% | 846,000 +17.09% | 722,515 +154.54% | |
Total Long-Term Assets | 562,000 -3.77% | 584,000 -30.97% | 846,000 +17.09% | 722,515 +123.75% | |
Total Assets | 689.8M +21.34% | 568.5M -3.36% | 588.2M +77.46% | 331.5M +277.60% | |
Income Taxes Payable | 101,000 -89.48% | 960,000 N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | 70.0M N/A | N/A N/A | N/A N/A | 300.0M N/A | |
Total Current Liabilities | 378.8M +64.64% | 230.1M +65.72% | 138.9M +43.80% | 96.6M +318.64% | |
Total Long-Term Debt | 117.7M -34.84% | 180.7M +1.48% | 178.1M +88.92% | 94.3M +92.01% | |
Total Long-Term Liabilities | 140.9M -24.54% | 186.8M +0.89% | 185.1M +96.38% | 94.3M +89.77% | |
Total Liabilities | 601.5M +17.60% | 511.5M +28.75% | 397.3M +79.01% | 221.9M +207.56% | |
Retained Earnings | -1.3B +16.31% | -1.1B +34.37% | -835.6M +40.12% | -596.3M +45.73% | |
Total Stockholders Equity | 88.3M +54.86% | 57.0M -70.15% | 191.0M +74.32% | 109.6M +600.92% | |
Total Shares Outstanding | 50.9M +4.55% | 48.7M +2.78% | 47.4M +8.86% | 43.5M +15.02% | |
Cash Flow | |||||
Cash from Operating Activities | -93.4M -27.26% | -128.4M -11.49% | -145.1M +24.52% | -116.5M +7.66% | |
Capital Expenditures | 480,000 +77.78% | 270,000 -53.61% | 582,000 -17.11% | 702,109 +128.29% | |
Cash from Investing Activities | -480,000 +77.78% | -270,000 -53.61% | -582,000 -98.92% | -53.7M +17,361.32% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 101.5M +75.42% | 57.8M -82.53% | 331.0M +16.32% | 284.6M +2,456.96% | |
Financials Ratio | |||||
Gross Margin | 92.51% +1.25% | 91.37% +1.10% | 90.37% +0.84% | 89.61% N/A | |
Operating Margin | -26.31% -63.83% | -72.74% -15.09% | -85.67% -76.16% | -359.33% N/A | |
Return on Assets | -29.11% -41.37% | -49.66% -4.55% | -52.02% -41.72% | -89.27% -6.24% | |
Return on Equity | -252.11% +8.84% | -231.63% +45.49% | -159.21% -46.75% | -298.97% +48.36% | |
Revenue Growth | 64.33% +51.24% | 42.53% -90.35% | 440.80% N/A | N/A N/A | |
Current Ratio | 1.55 -26.25% | 2.11 -41.95% | 3.63 +42.76% | 2.54 -32.18% | |
Cash Ratio | 0.85 -37.80% | 1.37 -50.72% | 2.78 +33.72% | 2.08 -44.52% | |
Debt-to-Equity Ratio | 2.13 N/A | N/A N/A | N/A N/A | 3.60 N/A | |
Debt-to-Assets Ratio | 0.27 N/A | N/A N/A | N/A N/A | 1.19 N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow